Investment Analysts’ Recent Ratings Changes for Tenet Healthcare (THC)

Tenet Healthcare (NYSE: THC) has recently received a number of price target changes and ratings updates:

• 8/15/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/14/2026 – Tenet Healthcare had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $285.00 price target on the stock.
• 8/11/2026 – Tenet Healthcare was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/10/2026 – Tenet Healthcare was given a new $290.00 price target by Mizuho.
• 8/3/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $231.00 to $281.00. They now have an “overweight” rating on the stock.
• 8/3/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/28/2026 – Tenet Healthcare had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $305.00 price target on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Truist Financial Corporation from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Guggenheim from $242.00 to $283.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Robert W. Baird from $210.00 to $280.00. They now have a “neutral” rating on the stock.
• 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Stephens. They now have a $285.00 price target on the stock.
• 7/27/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Tenet Healthcare was given a new $308.00 price target by Piper Sandler.
• 7/27/2026 – Tenet Healthcare had its price target raised by Morgan Stanley from $254.00 to $274.00. They now have an “overweight” rating on the stock.
• 7/27/2026 – Tenet Healthcare was given a new $270.00 price target by Raymond James Financial, Inc..
• 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/27/2026 – Tenet Healthcare had its price target raised by TD Cowen from $233.00 to $263.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Tenet Healthcare had its price target raised by Royal Bank Of Canada from $236.00 to $283.00. They now have an “outperform” rating on the stock.
• 7/26/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $240.00 to $271.00. They now have an “overweight” rating on the stock.
• 7/20/2026 – Tenet Healthcare had its price target lowered by Guggenheim from $252.00 to $242.00. They now have a “buy” rating on the stock.
• 7/18/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/13/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $213.00 to $231.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $238.00 to $240.00. They now have an “overweight” rating on the stock.
• 6/22/2026 – Tenet Healthcare had its price target lowered by TD Cowen from $242.00 to $233.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, Director Tammy Romo sold 4,922 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $264.15, for a total transaction of $1,300,146.30. Following the transaction, the director directly owned 30,784 shares of the company’s stock, valued at approximately $8,131,593.60. This trade represents a 13.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paola M. Arbour sold 10,878 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $243.90, for a total transaction of $2,653,144.20. Following the completion of the transaction, the executive vice president owned 18,413 shares of the company’s stock, valued at $4,490,930.70. This represents a 37.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 41,375 shares of company stock worth $9,793,347. 0.97% of the stock is owned by company insiders.

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.